No quick fix for Glaxo’s Walmsley despite results boost
Our equities expert ponders the path forward for one of the world’s pharmaceutical giants.
28th July 2021 16:35
by Graeme Evans from interactive investor
Our equities expert ponders the path forward for one of the world’s pharmaceutical giants.
There's clearly no quick fix for the GlaxoSmithKline (LSE:GSK) share price despite chief executive Emma Walmsley's big strategy overhaul and today's moderately better-than-expected half-year results.
The FTSE 100 index stock spent the first part of July above 1,400p but is back below the threshold a month after Walmsley’s review, when she promised a step-change in sales, operating profits growth and performance from 2022.
Her focus is on high quality vaccines and the specialty medicines portfolio, but for now there's continued frustration for investors — including customers who made Glaxo the third most popular stock on the ii platform — as shares fell back 9p to 1,390p today.
The decline came as Glaxo revealed that the recovery of its best-selling shingles jab Shingrix was taking longer than expected outside the United States, having been impacted by health centres prioritising Covid-19 vaccination programmes.
This means revenues for the vaccine division are expected to be flat across 2021, despite strong underlying demand for other products, which include protection against childhood diseases such as measles, meningitis and pneumonia.
- The hard work starts here for GlaxoSmithKline
- GlaxoSmithKline: aggressive growth to compensate for dividend cut
- Top 20 most-bought UK shares in Q2 2021
- Take control of your retirement planning with our award-winning, low-cost Self-Invested Personal Pension (SIPP)
Revenues from the use of Glaxo's adjuvant technology on several Covid-19 vaccines boosted the division in the second quarter, but overall the figure across the first half of the year was flat at £2.8 billion and 9% lower when excluding the pandemic vaccines.
Pharmaceuticals turnover of £8.1 billion for the first half was up 2% at constant exchange rates, led by growth from respiratory and HIV products and partly offset by declines in more established drugs as demand has also been affected by Covid-19.
Turnover across the group, including the consumer healthcare arm, came in at £15.5 billion for a fall of 1% on an underlying basis. The figure was 15% higher at £8.1 billion in the second quarter, helping adjusted earnings per share (EPS) to rise 71% to 28.1p.
The company still expects to see an EPS decline across the year in the mid to high single digits, excluding any contribution from Covid-19 products.
Walmsley is looking for “meaningful improvements” in revenues and margins starting next year, alongside the separation of the consumer healthcare arm in a long-awaited demerger.
Walmsley's medium-term targets in a strategy update last month included sales growth of more than 5% and an operating margin of over 30%.
The Glaxo divi, which is one of the most prized in the FTSE 100 index, is also being reset so the company can step up investment around vaccines and its speciality medicines in oncology, HIV and hard-to-treat diseases.
The dividend has been at 80p a share since 2014 for a current yield of 5.7%, with Walmsley today confirming the latest 19p a share quarterly instalment will be paid on 7 October.
The pay-out is being cut to about 55p next year for what should still equate to a yield of about 3.9%.
The remaining “New GSK” business is then expected to adopt a progressive dividend policy targeting a pay-out ratio equivalent to about 40%-60% of earnings, starting with 45p a share in 2023.
Glaxo is demerging 80% of its majority stake in the Sensodyne and Panadol consumer joint venture to Glaxo shareholders, with the new shares set for a premium listing in London.
The separation of a business that generated annual sales of more than £10 billion last year should take place by the middle of next year and lead to an £8 billion windfall payment to New GSK. The narrower focus will enable New GSK to further enhance an existing pipeline of 20 vaccines and 42 medicines, many of which it says are potential best or first in class opportunities.
These articles are provided for information purposes only. Occasionally, an opinion about whether to buy or sell a specific investment may be provided by third parties. The content is not intended to be a personal recommendation to buy or sell any financial instrument or product, or to adopt any investment strategy as it is not provided based on an assessment of your investing knowledge and experience, your financial situation or your investment objectives. The value of your investments, and the income derived from them, may go down as well as up. You may not get back all the money that you invest. The investments referred to in this article may not be suitable for all investors, and if in doubt, an investor should seek advice from a qualified investment adviser.
Full performance can be found on the company or index summary page on the interactive investor website. Simply click on the company's or index name highlighted in the article.